OUR PAPERS ON PUBMED
You can download all our papers at ResearchGate
SELECTED PAPERS
o Ondrisova L, Seda V, Hlavac K, Pavelkova P, Hoferkova E, Chiodin G, Kostalova L, Mladonicka Pavlasova G, Filip D, Vecera J, Zeni PF, Oppelt J, Kahounova Z, Vichova R, Soucek K, Panovska A, Plevova K, Pospisilova S, Simkovic M, Vrbacky F, Lysak D, Fernandes SM, Davids MS, Maiques-Diaz A, Charalampopoulou S, Martin-Subero JI, Brown JR, Doubek M, Forconi F, Mayer J,
Mraz M. FoxO1/Rictor axis induces a non-genetic adaptation to Ibrutinib via Akt activation in chronic lymphocytic leukemia.
J CLIN INVEST. 2024 Oct (epub). Impact factor: 13,3
o Hlavac K, Pavelkova P, Ondrisova L,
Mraz M. FoxO1 signaling in B cell malignancies and its therapeutic targeting.
FEBS Letters. 2024 Nov (epub). Review
o Hoferkova E, Seda V, Kadakova S, Verner J, Loja T, Matulova K, Skuhrova Francova H, Ondrouskova E, Filip D, Blavet N, Boudny M, Mladonicka Pavlasova G, Vecera J, Ondrisova L, Pavelkova P, Hlavac K, Kostalova L, Michaelou A, Pospisilova S, Dorazilova J, Chochola V, Jaros J, Doubek M, Jarosova M, Hampl A, Vojtova L, Kren L, Mayer J,
Mraz M. Stromal cells engineered to express T cell factors induce robust CLL cell proliferation in vitro and in PDX co-transplantations allowing the identification of RAF inhibitors as anti-proliferative drugs.
LEUKEMIA. 2024 June (epub). Impact factor: 12,8
o
Mraz M. 5'-UTR mRNA splicing determines CD20 levels.
BLOOD. . Commentary. 2023 Nov 16;142(20):1676-1678. Impact factor: 22
o Seda V, Vojackova E, Ondrisova L, Kostalova L, Sharma S, Loja T, Pavlasova G, Zicha D, Peskova MK, Krivanek J, Liskova K, Kren L, Benes V, Litzmanova K, Borsky M, Oppelt J, Verner J, Pospisilova S, Brychtova Y, Panovska A, Tan Z, Zhang S, Doubek M, Cerna K, Mayer J,
Mraz M. FoxO1-GAB1 Axis Regulates Homing Capacity and Tonic AKT Activity in Chronic Lymphocytic Leukemia.
BLOOD. 2021 March (epub). Impact factor: 25,5
o Sharma S, Pavlasova G, Seda V, Cerna K, Vojackova E, Filip D, Ondrisova L, Sandova V, Kostalova L, Zeni PF, Borsky M, Oppelt J, Liskova K, Kren L, Janikova A, Pospisilova S, Fernandes SM, Shehata M , Rassenti LZ, Jaeger U, Doubek M, Davids MS, Brown JR, Mayer J, Kipps TJ,
Mraz M. miR-29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: an Axis Affected by BCR inhibitors.
BLOOD. 2021 May. Impact factor: 25,5
o Deb R, Torres MDT, Boudny M, Koberska M, Cappiello F, Popper M, Dvorakova Bendova K, Drabinova M, Hanackova A, Jeannot K*, Petrik M*, Mangoni ML*, Balikova Novotna G*,
Mraz M*, de la Fuente-Nunez C*, Vacha R*. Computational Design of Pore-Forming Peptides with Potent Antimicrobial and Anticancer Activities.
J Med Chem. 2024 Aug 22;67(16):14040-14061. Impact factor: 6,8 *corresponding authors
o Dolnikova A, Kazantsev D, Klanova M, Pokorna E, Sovilj D, Kelemen CD, Tuskova L, Hoferkova E,
Mraz M*, Helman K, Curik N, Machova Polakova K, Andera L, Trneny M, Klener P. Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status.
BLOOD Adv. 2024 Jul 9;8(13):3532-3543. Impact factor: 7.6
o
Mraz M. Genetic mechanism for the loss of PRAME in B cell lymphomas.
J Clin Invest. 2022 Jul 15;132(14):e160983. Impact factor: 19.5
o Zeni PF,
Mraz M. LncRNAs in adaptive immunity: role in physiological and pathological conditions.
RNA Biol. 2021 May;18(5):619-632. Impact factor: 5
o Chiodin G, Drennan S, Martino EA, Ondrisova L, Henderson I, Del Rio L, Tracy I, D'Avola A, Parker H, Bonfiglio S, Scarfo L, Sutton LA, Strefford JC, Forster J, Brake O, Potter KN, Sale B, Lanham S,
Mraz M, Ghia P, Stevenson FK, Forconi F. High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in CLL patients..
BLOOD Advances. 2022 May (epub). Impact factor: 6,5
o Khirsariya P, Pospisil P, Maier L, Boudny M, Babas M, Kroutil O,
Mraz M, Vacha R, Paruch K. Synthesis and Profiling of Highly Selective Inhibitors of Methyltransferase DOT1L Based on Carbocyclic C-Nucleosides.
J Med Chem. 2022 Apr 14;65(7):5701-5723.. Impact factor: 7,5
o Hoferkova E, Kadakova S,
Mraz M. In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.
Cancers 2022, 14(13), 3087, epub. (review) Impact factor: 6,1
o Sandova V, Pavlasova GM, Seda V, Cerna KA, Sharma S, Palusova V, Brychtova Y, Pospisilova S, Fernandes SM, Panovska A, Doubek M, Davids MS, Brown JR, Mayer J,
Mraz M. IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K? inhibitor idelalisib
Haematologica. 2021 Jul 1 (epub). Impact factor: 10
o Lobello C, Tichy B, Bystry V, Radova L, Filip D,
Mraz M, Montes-Mojarro IA, Prokoph N, Larose H, Liang HC, Sharma GG, Mologni L, Belada D, Kamaradova K, Fend F, Gambacorti-Passerini C, Merkel O, Turner SD, Janikova A, Pospisilova S.STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.
LEUKEMIA.. 2021 May;35(5):1500-1505. Impact factor: 12,8
o Borsky M, Hrabcakova V, Novotna J, Brychtova Y, Doubek M, Panovska A, Muller P, Mayer J, Trbusek M,
Mraz M. Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion
Leukemia Res. 2021 Aug 4 (epub). Impact factor: 3,2
o Pavlasova G,
Mraz M. The regulation and function of CD20: an 'enigma' of B-cell biology and targeted therapy
Haematologica. 2020 Oct 26;10:591577. Review. Impact factor: 7,8
o Ondrisova L,
Mraz M. Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies
Front Oncology. 2020 June (epub). Review. Impact factor: 5
o Fedorova V, Amruz Cerna K, Oppelt J, Pospisilova V, Barta T,
Mraz M, Bohaciakova D. MicroRNA Profiling of Self-Renewing Human Neural Stem Cells Reveals Novel Sets of Differentially Expressed microRNAs During Neural Differentiation In Vitro.
Stem Cell Rev Rep. 2023 Jul;19(5):1524-1539. Impact factor: 3,8
o Musilova K, Devan J, Cerna K, Seda V, Pavlasova G, Sharma S, Oppelt J, Pytlik R, Prochazka V, Prouzova Z, Trbusek M, Zlamalikova L, Liskova K, Kruzova L, Jarosova M, Mareckova A, Kornauth C, Simonitsch-Klupp I, Schiefer AI, Merkel O, Mocikova H, Burda P, Machova Polakova K, Kren L, Mayer J, Zent CS, Trneny M, Evans AG, Janikova A,
Mraz M. miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels.
Blood. 2018 Sep 13 (epub). Impact factor: 15,1
o Pavlasova G, Borsky M, Svobodova V, Oppelt J, Cerna K, Novotna J, Seda V, Fojtova M, Fajkus J, Brychtova Y, Doubek M, Pospisilova S, Mayer J,
Mraz M. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels.
Leukemia. 2018 Jul 20 (epub). Impact factor: 10
o Cerna K, Oppelt J, Chochola V, Musilova K, Seda V, Pavlasova G, Radova L, Arigoni M, Calogero RA, Benes V, Trbusek M, Brychtova Y, Doubek M, Mayer J, Pospisilova S,
Mraz M. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells.
Leukemia. 2019 Feb;33(2):403-414. Impact factor: 10
o Devan J, Janikova A,
Mraz M. New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs (review).
Seminars in Oncology. 2018 Oct 22. (epub). Impact factor: 5
o Filip D,
Mraz M. The role of MYC in the transformation and aggressiveness of 'indolent' B-cell malignancies (review).
Leukemia and Lymphoma. 2019 Oct 20:1-15. (epub).
o
Mraz M, Pospisilova S. Detection of a deletion at 22q11 locus involving ZNF280A/ZNF280B/PRAME/GGTLC2 in B-cell malignancies: simply a consequence of an immunoglobulin lambda light chain rearrangement.
British Journal of Haematology. 2019 (epub). Impact factor: 5,1
o Cerna K,
Mraz M. p53 limits B cell receptor (BCR) signalling: a new role for miR-34a and FOXP1 (Editorial).
Oncotarget. 2018 (in press). Impact factor: 5,2
o Boudny M, Zemanova J, Khirsariya P, Borsky M, Verner J, Cerna J, Oltova A, Seda V,
Mraz M, Jaros J, Jaskova Z, Spunarova M, Brychtova Y, Soucek K, Drapela S, Kasparkova M, Mayer J, Paruch K, Trbusek M. Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells.
Haematologica. 2019 Apr 11 (epub). Impact factor: 9.1
o Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR,
Mraz M. Ibrutinib inhibits CD20 up-regulation on CLL B cells mediated by the CXCR4/SDF-1 axis.
Blood. 2016 Aug 1 (epub).Impact factor: 12
o Musilova K,
Mraz M. MicroRNAs in B cell lymphomas: How a complex biology gets more complex.
Leukemia.2015 May;29(5):1004-17.Impact factor: 9,4
o
Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ. MicroRNA-150 contributes to the proficiency of B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1 genes.
Blood. 2014 Jul 3;124(1):84-95. Impact factor: 9,8
o Cui B, Chen L, Zhang S,
Mraz M, Fecteau JF, Yu J, Ghia EM, Zhang L, Bao L, Rassenti LZ, Messer K, Calin GA, Croce CM, Kipps TJ. MicroRNA-155 Influences B-cell Receptor Signaling And Associates With Aggressive Disease In Chronic Lymphocytic Leukemia.
Blood. 2014 Jul 24;124(4):546-54.Impact factor: 9,8
o Seda V,
Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells.
Eur J Haematol. 2015 Mar;94(3):193-205.Impact factor: 2,4
o Stamatopoulos B, Smith T, Crompot E, Pieters K, Clifford R,
Mraz M, Robbe P, Burns A, Timbs A, Bruce D, Hillmen P, Meuleman N, Mineur P, Firescu R, Maerevoet M, De Wilde V, Efira A, Philippe J, Verhasselt B, Offner F, Sims D, Heger A, Dreau H, Schuh A. The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study.
Clin Cancer Res.. 2018 Oct 15;24(20):5048-5057.; Impact factor: 10
o
Mraz M, Pospisilova S. MicroRNAs in chronic lymphocytic leukemia: from causality to associations and back.
Expert Rev Hematol. 2012 Dec;5(6):579-81. Editorial
o
Mraz M, Kipps T. MicroRNAs And B Cell Receptor Signaling in Chronic Lymphocytic Leukemia.
Leukemia and Lymphoma 2013 Aug;54(8):1836-9. Impact factor: 2,6
o Dolezalova D,
Mraz M*, Barta T, Plevova K, Vinarsky V, Holubcova Z, Jaros J, Dvorak P, Pospisilova S, Hampl A. MicroRNAs Regulate p21(Waf1/Cip1) Protein Expression and the DNA Damage Response in Human Embryonic Stem Cells.
Stem Cells. 2012;30(7):1362-72.;
*shared first author and corresponding author, Impact factor: 7,781
Peskova L, Cerna K, Oppelt J,
Mraz M, Barta T. Oct4-mediated reprogramming induces embryonic-like microRNA expression signatures in human fibroblasts.
Scientific Reports 2019 Oct 31;9(1):15759.<
o
Mraz M*, Dolezalova D, Plevova K, Stano Kozubik K, Mayerova V, Cerna K, Musilova K, Tichy B, Pavlova S, Borsky M, Verner J, Doubek M, Brychtova Y, Trbusek M, Hampl A, Mayer J, Pospisilova S.MicroRNA-650 expression is influenced
by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia.
Blood. 2012 Mar 1;119(9):2110-3. *first and corresponding author; Impact factor: 10,56
o
Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S, Ansell SM, Novak AJ, Kay NE, Witzig TE, Nowakowski GS. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin
alfa-4-beta-1 (VLA-4) with natalizumab can overcome this resistance.
Br J Haematol. 2011;155(1):53-64.; Impact factor: 4,9419
o
Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, Stano Kozubik K, Smardova J, Brychtova Y, Doubek M, Trbusek M, Mayer J, Pospisilova S. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53
abnormalities.
Leukemia. 2009;23(6):1159-63.; Impact factor: 8.966 58
o Vargova K, Curik N, Burda P, Basova P, Kulvait V, Pospisil V, Savvulidi F, Kokavec J, Necas E, Berkova A, Obrtlikova P, Karban J,
Mraz M, Pospisilova S, Mayer J, Trneny M, Zavadil J, Stopka T. MYB transcriptionally regulates
the miR-155 host gene in chronic lymphocytic leukemia.
Blood. 2011;117(14):3816-25.; Impact factor: 10,56
o Trbusek M, Smardova J, Malcikova J, Sebejova L, Dobes P, Svitakova M, Vranova V,
Mraz M, Skuhrova Francova H, Doubek M, Brychtova Y, Kuglik P, Pospisilova S, Mayer J. Missense Mutations Located in Structural p53 DNA-binding
Motifs Are Associated with Extremely Poor Survival in Chronic Lymphocytic Leukemia.
Journal of Clinical Oncology. 2011;29(19):2703-8.; Impact factor: 18,9
o Dolezalova D,
Mraz M, Hampl A. miRNA in Embryonic Stem Cells.
In MICRORNA IN REGENERATIVE MEDICINE 2015 (Elsevier Inc.) (chapter in book)
